NCT04143126Active, not recruiting
Promoting Activity and Cognitive Enrichment in Schizophrenia (PACES)
Cognitive Enhancement for Persistent Negative Symptoms in Schizophrenia
Source: ClinicalTrials.gov · Last updated 15 Jun 2026
Brief summary (registry, in English)
This project will conduct a confirmatory efficacy trial of two novel psychosocial interventions, Cognitive Enhancement Therapy and Enriched Supportive Therapy, for the treatment of persistent negative symptoms in schizophrenia.
- Status (registry)
- Active, not recruiting
- Study type
- Interventional
- Enrollment
- 90 (estimated)
- First submitted
- 24 Oct 2019
- Start date
- 1 Oct 2019
- Primary completion date
- 30 Jun 2027
- Lead sponsor
- University of Pittsburgh
- Diseases
- Schizophrenia
- NCT number
- NCT04143126
What you commit to
- Study type: Interventional
- Planned participants: 90
- From 1 Oct 2019 to the primary completion date, 30 Jun 2027
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- comorbid medical disorders producing cognitive impairment (e.g., mild brain injury, previous concussions with loss of consciousness);
- significant clinician-estimated medication non-adherence; and
Other illness
- the presence of organic brain syndrome;
- SCID-verified substance use disorder.
Other
- persistent suicidal or homicidal behavior;
Who the study is looking for
- are between 18-60 years of age;
- have a diagnosis of schizophrenia or schizoaffective disorder confirmed by the SCID;
- have a clinical history of persistent negative symptoms lasting at least 3 months as identified from the medical record;
- have observed persistent negative symptoms at the beginning and end of the 4-week evaluation period;
- have been stabilized on antipsychotic medication at the beginning and end of the 4-week evaluation period;
- have stabilized depressive symptoms at the beginning and end of the 4-week evaluation period;
- have mild or absent extrapyramidal symptoms at the beginning and end of the 4-week evaluation period;
- have had changes to their primary antipsychotic medication within the previous 3 months;
- have current IQ \> 80; and
- are able to read (sixth grade level or higher) and speak fluent English. -
Age in the registry: 18 years to 60 years · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| University of Pittsburgh Coordinator of this site? Confirm its status | Pittsburgh | United States | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.